Sermorelin is marketed to men more than to anyone else, usually as a way to feel and look younger without taking growth hormone itself. The human evidence behind that pitch comes from about thirty older men across three small studies, all published in the 1990s. Here is what those men were given, what changed for them, and how far the results stretch to a man deciding today.
What does sermorelin do for men?
It signals the pituitary to release more of the body’s own growth hormone, and in older men it reliably does that. In the one trial with body-composition data, nine men aged 55 to 71 took it nightly for 16 weeks after a placebo run-in. Their nighttime growth hormone output rose (P < 0.05), and so did lean body mass, insulin sensitivity, general well-being and libido. The ten women in the same study did not show the lean-mass, insulin-sensitivity, well-being or libido changes [1]. How each of those outcomes compares by sex is set out in sermorelin’s benefits, outcome by outcome; this page stays with the men.
The men-only result is the main reason sermorelin is pitched to men. It is also a narrow one. Nine people is a small group, and the lean mass gain was statistically significant but its size in kilograms is not given in the published abstract. Treat it as a signal that the drug can move body composition in older men, not as a forecast for any one man.
What happened in the trials that enrolled only men?
Two other studies gave sermorelin’s exact peptide, GHRH(1-29), to men only, and they are the more useful ones for a man weighing a prescription, because they tested different doses and schedules.
In 1992, ten healthy men averaging 68 years old took the peptide by injection twice a day for 14 days at two doses, 0.5 mg and 1 mg, in random order. At the higher dose, average 24-hour growth hormone and IGF-1 rose significantly (IGF-1 at P < 0.005). Afterward, the older men’s levels were no longer different from those of nine healthy men averaging 26 years old. The lower dose did not reach significance. Fasting glucose did not change [2].
In 1997, eleven healthy men aged 64 to 76, chosen because their IGF-1 was low, injected 2 mg once nightly for six weeks. Nighttime growth hormone rose (P < 0.02), but IGF-1 did not. Two of six strength measures improved, the upright row and the shoulder press, as did an abdominal endurance test. Body composition, weight, glucose and lipids did not change, and no significant side effects were seen. The authors concluded that a single nightly dose was “less effective than multiple daily doses” [3].
Why do older men respond to sermorelin at all?
The premise behind all three trials is that an older man’s pituitary still works; it just receives a weaker signal. The 1992 study tested that directly. Before treatment, the older men produced shorter growth hormone pulses and had lower IGF-1 than the younger men (IGF-1 at P < 0.0001). Yet when both groups were given an intravenous dose of GHRH, the peak and total growth hormone responses did not differ by age [2]. The gland answered as well at 68 as at 26.
That is the strongest argument for the drug in men, and it also sets its limit. Sermorelin can only amplify what the pituitary is able to release. A man whose growth hormone is low because of pituitary damage, surgery or radiation is in a different situation, which is why a prescriber may want to know the cause before starting. The lab test that shows whether the extra signal is reaching the liver is IGF-1, explained in sermorelin and IGF-1 testing.
What dose of sermorelin is used for men?
No dose has been set for men, because no dose-finding study has been run in men of any age. The three trials used three different approaches. The 1997 mixed-sex trial used 10 micrograms per kilogram of body weight each night [1], which works out to about 800 micrograms for an 80 kg man and about 1,000 for 100 kg. The 1992 study needed 1 mg twice a day to restore younger-man levels [2]. The second 1997 study used 2 mg once a night and saw no IGF-1 change [3].
Two things follow. Trial doses were weight-based or larger than the flat nightly amounts most sellers advertise, a gap shown in the published dose versus the marketed one. And frequency may matter as much as amount, which is a question to put to a prescriber directly. The dose-by-weight tool shows what the 1997 trial dose would be at your weight.
Does sermorelin raise testosterone?
None of the three trials reported that it does. The 1992 study measured testosterone and found it lower in the older men at baseline (P < 0.01), but did not report a change during treatment [2]. The 1997 mixed-sex trial did not measure testosterone at all, so its libido finding is a questionnaire score rather than a hormone result. The difference between the two hormones, and why one is not a substitute for the other, is covered in sermorelin vs. testosterone.
Can men take sermorelin with TRT?
Many men who ask about sermorelin are already on testosterone replacement, and the evidence on that combination is a single chart review. Fourteen men on testosterone therapy, average age 33, took sermorelin together with two other growth hormone secretagogues three times a day. Over an average of 134 days their IGF-1 rose from 159.5 to 239.0 ng/mL (P < 0.0001) [4]. Men who also took an aromatase inhibitor or tamoxifen saw smaller rises.
That is the only published data on younger men, on TRT, and on the kind of multi-peptide regimen men are often sold. It was not controlled, it tracked a blood marker rather than body composition, and three drugs were given at once. It shows the combination raises IGF-1. It does not show what that does for muscle, fat or energy. Which medicines can change the response is covered in what not to mix with sermorelin.
What side effects do men report on sermorelin?
In the trials, very few. The only adverse effect the 1997 mixed-sex trial reported was a temporary rise in blood lipids that resolved by the end of the study [1]. The men-only studies reported no significant side effects and no change in fasting glucose [2] [3]. None of these studies ran longer than about five months, so long-term safety in men is simply unmeasured. The wider picture, including the pediatric data, is in sermorelin side effects.
One question is specific to men. Growth hormone and IGF-1 are growth factors, and the label of tesamorelin, an approved drug in the same class, says active cancer is a reason not to use it and that any past cancer should be inactive and treated first [5]. That is tesamorelin’s label, not sermorelin’s. Men with a history of prostate or other cancer should raise it before starting; see who should not take sermorelin.
Is sermorelin worth it for men under 50?
The evidence does not reach that far. Every controlled trial enrolled men 55 or older, and the 1992 study included younger men only as an untreated comparison group [2]. Growth hormone output falls with age, which is the premise of all three trials; a man in his thirties starts from a different baseline, and nobody has measured what an added nightly pulse does for him. That is an unknown, not a negative result. It does mean a younger man is paying for an extrapolation, a point taken further in the age range sermorelin was tested in.
For men who decide to try it, the practical steps are the same at any age: a baseline IGF-1 so there is something to compare against, a prescriber who will discuss dose and frequency rather than hand over a flat protocol, and a plan to recheck after a few months. For sport, note that sermorelin is banned at all times by the World Anti-Doping Agency, which sermorelin and drug testing explains. Compare the sellers that offer it on the sermorelin injections board.